Regeneron Pharmaceuticals (REGN) Interest & Investment Income (2009 - 2026)

Regeneron Pharmaceuticals' Interest & Investment Income history runs 18 years deep, the most recent figure standing at -$48.0 million for Q2 2026.

• In Q2 2026, Interest & Investment Income fell 317.19% year-over-year to -$48.0 million; the TTM figure through Jun 2026 stood at -$91.0 million (down 174.35% YoY), while the FY2025 annual figure was $83.0 million, up 12.77% from the prior year.
• Interest & Investment Income for Q2 2026 stood at -$48.0 million, up from -$65.8 million in the prior quarter.
• The five-year high for Interest & Investment Income was $128.2 million in Q3 2024, with the low at -$144.9 million in Q1 2022.
• The 5-year median for Interest & Investment Income is $7.5 million (2024), against an average of -$700000.0.
• The sharpest annual moves came in 2022 and 2025: Interest & Investment Income slumped 6612.5% in 2022, then jumped 988.57% in 2025.
• Regeneron Pharmaceuticals' Interest & Investment Income stood at $36.3 million in 2022, then soared by 162.81% to $95.4 million in 2023, then plunged by 169.18% to -$66.0 million in 2024, then soared by 110.76% to $7.1 million in 2025, then slumped by 776.06% to -$48.0 million in 2026.
• Business Quant data shows REGN's Interest & Investment Income at -$48.0 million in Q2 2026, -$65.8 million in Q1 2026, and $7.1 million in Q4 2025.